VYNE Therapeutics Inc. (VYNE)

Market Cap	19.05M -21.7%
Revenue (ttm)	454,000 -25.0%
Net Income	-21.46M
EPS	-25.07
Shares Out	667.06K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,293
Open	25.50
Previous Close	25.45
Day's Range	23.37 - 28.56
52-Week Range	14.03 - 79.75
Beta	2.01
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About VYNE

As of July 27, 2026, VYNE Therapeutics Inc. was acquired by Yarrow Bioscience, Inc., in a reverse merger transaction. VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company’s lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 25, 2018
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: VYNE
• Website: https://vynetherapeutics.com

Financial Performance

In 2025, VYNE Therapeutics's revenue was $570,000, an increase of 13.77% compared to the previous year's $501,000. Losses were -$26.48 million, -33.52% less than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jan 1, 2000

Data Sources Report a data error